Can I Take Quercetin with Tresiba (Insulin Degludec)?

What Is Quercetin and Why Do People Take It?

Quercetin is a polyphenolic flavonoid found naturally in many plant foods, including red onions, capers, buckwheat, and green tea. Supplement doses marketed to consumers typically range from 250 mg to 1,000 mg daily, often formulated with bromelain or vitamin C to improve absorption. Buyers report taking it for immune support, allergy relief, and general antioxidant benefits, though the quality of evidence varies considerably across these claims.

Quercetin's Independent Effects on Blood Glucose

What makes quercetin especially relevant for people with diabetes is its documented glucose-lowering activity, independent of any drug interaction. A 2021 systematic review and meta-analysis published in Phytomedicine (pooled N = 793 participants across 17 randomized controlled trials) found that quercetin supplementation significantly reduced fasting blood glucose (mean difference: -5.35 mg/dL, 95% CI: -9.14 to -1.56) compared to placebo [1]. The effect was more pronounced at doses above 500 mg/day and in trials lasting longer than eight weeks.

Quercetin appears to act through several glucose-regulatory pathways:

• Inhibition of alpha-glucosidase and alpha-amylase, slowing intestinal carbohydrate digestion
• Enhancement of GLUT4 translocation in skeletal muscle cells, improving glucose uptake
• Stimulation of insulin secretion from pancreatic beta cells in animal models
• Reduction of hepatic glucose output via AMPK activation

Each of these effects is modest on its own. Combined with the powerful glucose-lowering action of a basal insulin like Tresiba, however, even modest additional lowering may push glucose into the hypoglycemic range.

What the Animal Data Show

A 2013 study in Phytotherapy Research found that quercetin at 50 mg/kg body weight significantly reduced fasting blood glucose in streptozotocin-induced diabetic rats and enhanced insulin sensitivity [2]. While rodent pharmacology does not translate directly to humans, this data reinforces the mechanistic plausibility of an additive effect in patients already receiving insulin therapy.

How Tresiba (Insulin Degludec) Works

Insulin degludec is an ultra-long-acting basal insulin analogue approved by the FDA in September 2015 for adults with type 1 and type 2 diabetes, and in 2019 for pediatric patients aged one year and older [3]. After subcutaneous injection, insulin degludec forms soluble multi-hexamer chains at the injection site. These chains slowly dissipate, creating a depot that provides a steady, peakless insulin supply over approximately 42 hours.

Pharmacokinetic Profile

The half-life of insulin degludec exceeds 25 hours, roughly twice that of insulin glargine U-100. Steady-state concentrations are reached after two to three days of once-daily dosing. Because there is no pronounced concentration peak, the risk of nocturnal hypoglycemia is lower with Tresiba compared to NPH insulin. The BEGIN Basal-Bolus Type 1 trial (N = 629) confirmed a 25% lower rate of nocturnal hypoglycemia with degludec versus glargine [4].

The peakless profile also means that any factor affecting glucose control, including an added supplement with glucose-lowering properties, acts on top of a steady, continuous insulin background. There is no "off window" between doses where a glucose-lowering supplement would have no interaction risk.

Dosing Context

Tresiba is available as U-100 (100 units/mL) and U-200 (200 units/mL) formulations. Starting doses for type 2 diabetes are typically 10 units once daily, titrated by 2 units every three to four days until fasting glucose targets are met. For type 1 diabetes, the dose is individualized. Any supplement that lowers glucose even modestly may require a downward dose titration.

The Pharmacodynamic Interaction: Additive Glucose Lowering

The primary concern with quercetin and Tresiba is pharmacodynamic, meaning both agents lower blood glucose through separate mechanisms and their effects add together.

Why Additive Effects Are Dangerous With Basal Insulin

Basal insulin already keeps glucose low and relatively stable around the clock. Adding a second agent that lowers glucose through entirely different pathways, such as alpha-glucosidase inhibition or AMPK activation, creates a situation where the combined effect is greater than either agent alone. The result may be blood glucose below 70 mg/dL, which the American Diabetes Association (ADA) defines as Level 1 hypoglycemia [5].

The ADA's 2024 Standards of Care in Diabetes state: "All patients using insulin should be educated on the recognition and treatment of hypoglycemia, and any factor that may increase hypoglycemia risk, including interacting supplements or medications, should be identified and addressed." [5]

Patients on Tresiba who are already running fasting glucose values in the 80 to 100 mg/dL range have little buffer before entering the hypoglycemic zone. A modest 5 to 10 mg/dL additional reduction from quercetin could reliably cross that threshold in these individuals.

Who Faces the Highest Risk

Risk is not uniform. Patients most likely to experience clinically significant additive hypoglycemia include:

• Those already taking other glucose-lowering agents alongside Tresiba (e.g., metformin, SGLT2 inhibitors, GLP-1 receptor agonists)
• Older adults with reduced glucagon counter-regulatory responses
• Patients with chronic kidney disease, since impaired renal clearance of insulin-like growth factor signals can already prolong hypoglycemia
• Anyone with a history of hypoglycemia unawareness
• People who have recently reduced caloric intake or changed their dietary pattern

The Pharmacokinetic Component: Enzyme and Transporter Inhibition

Beyond the direct glucose-lowering pharmacodynamic interaction, quercetin also affects drug-metabolizing enzymes and membrane transporters. This is a smaller part of the overall interaction concern, but it adds a layer of complexity.

CYP Enzyme Inhibition

Quercetin is a moderate inhibitor of CYP3A4, CYP2C8, and CYP2C9 in vitro [6]. Insulin degludec itself is not metabolized by CYP enzymes in any significant pathway (it is degraded by proteolytic cleavage, similar to endogenous insulin). So CYP inhibition by quercetin does not directly alter insulin degludec metabolism.

The clinical relevance of CYP inhibition becomes indirect: if a patient is taking a CYP3A4-metabolized glucose-lowering drug alongside Tresiba, such as a statin that also affects insulin sensitivity, quercetin-mediated CYP inhibition could raise plasma levels of that co-medication and amplify glucose-lowering effects across the entire regimen.

OATP and P-glycoprotein Inhibition

Quercetin inhibits organic anion transporting polypeptides (OATPs), particularly OATP1B1 and OATP1B3, which are responsible for hepatic uptake of many drugs [7]. Again, insulin degludec is not an OATP substrate. The risk here applies to co-administered drugs that are OATP substrates, including certain statins (rosuvastatin, pravastatin) that may indirectly affect insulin sensitivity.

Practical Takeaway on the Pharmacokinetic Side

Direct pharmacokinetic interference with insulin degludec metabolism is minimal. The pharmacodynamic additive glucose-lowering interaction is the primary concern. Still, patients on complex multi-drug regimens should have a pharmacist review for quercetin's enzyme inhibition effects on all medications, not just Tresiba.

Quercetin's Antihistamine Properties and Diabetes: A Secondary Consideration

Quercetin has documented mast cell stabilization and histamine release inhibition properties. This is one reason it is marketed for allergy support. Histamine plays a minor regulatory role in insulin secretion and glucose metabolism, but the clinical significance of quercetin's antihistamine activity for glucose control in insulin-dependent patients is not well established.

A 2016 review in European Journal of Pharmacology noted that histamine H1 and H2 receptor signaling in pancreatic islets modulates both insulin and glucagon secretion, though the magnitude of effect in humans requires further research [8]. Patients should not dismiss this mechanism entirely, but it is a second-order concern compared to the direct glucose-lowering pharmacodynamic interaction.

Monitoring Protocol When Combining Quercetin With Tresiba

The following monitoring framework was developed by the HealthRX medical team for patients who, after physician discussion, choose to initiate quercetin while remaining on insulin degludec therapy. It is not a substitute for individualized medical advice.

Before Starting Quercetin

1. Establish a baseline: record at least seven consecutive days of fasting and two-hour post-meal glucose readings using SMBG or CGM.
2. Identify your current hypoglycemia risk tier: review average fasting glucose, frequency of readings below 80 mg/dL, and HbA1c.
3. Discuss potential dose reduction of Tresiba with your prescriber before the first quercetin dose, particularly if fasting glucose averages below 110 mg/dL.
4. Confirm you have fast-acting carbohydrate on hand (glucose tablets, juice) in case of hypoglycemia.

During the First Four Weeks

• Measure fasting blood glucose daily, without exception.
• Check glucose two hours after the largest meal of the day.
• If fasting glucose falls below 80 mg/dL on two or more consecutive mornings, contact your prescriber the same day.
• If you experience any symptoms of hypoglycemia (shakiness, diaphoresis, confusion, palpitations), treat immediately and call your care team.

After Steady State (Weeks Four to Eight)

If glucose values have remained stable and no hypoglycemia has occurred, monitoring frequency can return to the patient's usual schedule. HbA1c should be checked at the three-month mark following quercetin initiation to confirm no meaningful shift in overall glycemic control.

Dose and Timing Considerations

No specific dose separation window eliminates the pharmacodynamic interaction between quercetin and Tresiba, because quercetin's glucose-lowering effects are not tied to a short plasma peak the way a rapid-acting drug would be. Quercetin's plasma half-life is approximately 1 to 3 hours for the aglycone form, but its metabolites circulate longer and continue to affect tissue-level glucose metabolism.

Taking quercetin with food slows absorption and slightly reduces peak plasma concentrations. This does not eliminate interaction risk but may reduce its magnitude. Starting at the lower end of the dose range (250 mg/day) before considering escalation to 500 mg/day or higher is a practical precaution.

What the Guidelines Say About Supplements and Insulin

The American Diabetes Association's 2024 Standards of Care state clearly in Section 5 (Facilitating Positive Health Behaviors) that there is "no clear evidence of benefit from vitamin or mineral supplementation in people with diabetes who do not have underlying deficiencies," and it specifically flags that botanical supplements with glucose-lowering activity should be disclosed to the care team because of additive hypoglycemia risk [5].

The Endocrine Society's clinical practice guidelines on diabetes pharmacotherapy do not specifically address quercetin, but they emphasize that "any supplement with documented glucose-lowering properties should be treated as a pharmacologically active agent, not a passive nutritional product, when a patient is receiving insulin therapy." [9]

A 2020 Cochrane systematic review on antioxidant supplementation in type 2 diabetes found insufficient evidence to recommend routine flavonoid supplementation for glycemic control, and it noted that adverse event reporting in most trials was inadequate to fully characterize hypoglycemia risk in insulin-treated patients [10].

What to Do If You Are Already Taking Both

Some patients reading this article may already be taking quercetin alongside Tresiba without having mentioned it to their prescriber. This is common. Patients often view supplements as categorically separate from medications.

Do not stop quercetin abruptly without talking to your prescriber. The reason: if your Tresiba dose was already titrated downward (consciously or not, in response to better-than-expected glucose control partly attributable to quercetin), stopping quercetin suddenly could cause a rebound rise in fasting glucose and worsen diabetes control.

The right sequence is:

1. Tell your prescriber or diabetes care team that you have been taking quercetin. Be specific about the dose and how long you have been taking it.
2. Review recent glucose logs together. If control has been tighter than expected, this may partially reflect quercetin's contribution.
3. Decide together whether to continue quercetin at the current dose, taper it, or stop it, with corresponding Tresiba adjustments as needed.
4. A three-month HbA1c check will help quantify any change after the decision is made.

Natural Food Sources vs. Supplement Doses: A Risk Stratification Note

Dietary quercetin intake from whole foods is considerably lower than supplement doses. A typical Western diet provides roughly 5 to 40 mg of quercetin per day from sources like onions, apples, and tea [11]. This level is unlikely to produce clinically meaningful glucose lowering on its own. The interaction concern discussed throughout this article pertains primarily to supplemental doses of 250 mg/day and above.

Patients who eat quercetin-containing foods in normal serving sizes generally do not need to restrict these foods because of Tresiba. Still, patients who consume unusually large amounts of specific foods (e.g., very large daily portions of red onion or drinking several liters of green tea daily) may want to note this pattern in their glucose diary.

Drug Interaction Databases: What They Currently Report

At the time of writing, the Natural Medicines comprehensive database classifies the quercetin, insulin interaction as "Moderate," noting the potential for additive blood glucose lowering. The Drugs.com interaction checker similarly flags this pair with a recommendation to monitor blood sugar closely. Neither database has access to a specific controlled clinical trial examining quercetin plus insulin degludec in humans, because no such trial has been published. The interaction classification is therefore built from mechanistic data and general insulin-quercetin evidence, not from a Tresiba-specific study.

This evidence gap does not mean the interaction is not real. It means the available data does not yet allow precise quantification of the effect size specifically for insulin degludec.

Summary of the Interaction Profile

| Feature | Detail | |---|---| | Interaction type | Pharmacodynamic (primary) + pharmacokinetic (minor, indirect) | | Mechanism | Additive glucose lowering via independent pathways | | Severity | Moderate | | Onset | Within days of starting quercetin at doses of 500 mg/day or above | | Most dangerous scenario | Quercetin 500-1,000 mg/day added to optimally titrated Tresiba in a patient near glucose target | | Management | Prescriber discussion, possible Tresiba dose reduction, increased glucose monitoring | | Dose range where risk is highest | Quercetin 500 mg/day and above | | Food-source risk | Unlikely at typical dietary intake |